Google’s Secret Trademark Filing Hints at New AI for Analyzing DNA
Google is working on something big.
And they didn’t want anyone to know about it.
Last fall, the company quietly filed a trademark in Tonga for “AlphaNucleo.“
According to the application, AlphaNucleo is an artificial intelligence platform designed to analyze DNA sequences, RNA sequences, and genetic variants. More importantly, it claims the system can predict biological properties based on that analysis.
If true, this isn’t just a new AI.
It’s a potential leap forward in how we understand the human genome.
And how we treat disease.
Why was the trademark filed in Tonga?
We are just learning of this trademark filing today because Google filed a trademark application with the United States Patent and Trademark Office (“USPTO”) on April 30, 2025.
The USPTO filing indicates that the trademark was originally filed on October 31, 2024, in Tonga.
That’s right. Tonga.
This may seem odd at first. But it’s a calculated legal maneuver—and a very clever one.
Thanks to a global treaty called the Paris Convention, companies can file a trademark in any one of over 170 member countries and then “claim priority” on that filing in another member country—as long as they do so within six months.
In other words, by filing first in Tonga, Google secured priority rights to the name “AlphaNucleo” dating back to Halloween 2024, even though the U.S. filing just appeared this week.
So, why file in Tonga and not a more well-known (or populated) country?
Because no one is looking there.
Tonga’s trademark database is not searchable online. Unlike the U.S., Europe, or other major jurisdictions, there’s no easy way for journalists, competitors, or analysts to monitor new filings. This makes Tonga an ideal place to quietly lock down a trademark without triggering buzz or headlines.
It’s the legal equivalent of planting a flag in a remote outpost—quietly, deliberately, and far from view.
Google’s US trademark application for “AlphaNucleo”
Will AlphaNucelo be a medical game-changer?
The technology described in the filing would allow AlphaNucleo to evaluate millions of genetic sequences and variations and make predictions about their significance. That means identifying whether a mutation is harmless—or potentially the cause of a serious condition.
Scientists and researchers have been looking for tools that can help them diagnose rare diseases faster, uncover hidden genetic risk factors, or personalize treatments based on individual DNA. If AlphaNucleo delivers on even a fraction of that promise, it could transform genomics, precision medicine, and healthcare as a whole.
Google hasn’t commented on the filing. But, the language in the application closely mirrors the kind of work already being done by DeepMind, Google’s AI research lab.
DeepMind’s AlphaFold project broke scientific ground by predicting protein structures with remarkable accuracy. “AlphaNucleo” may represent a next-generation leap—one that focuses not on proteins, but on the genetic code itself.
A glimpse behind the curtain
Google’s secretive filing strategy for this trademark suggests something big is in motion.
Trademark filings are often a company’s first public breadcrumb when a new product or platform is on the horizon. In this case, the filing tells us three things:
- The name “AlphaNucleo” has been selected and Google’s legal team has been tasked with protecting the trademark.
- The concept is serious enough to warrant an international legal strategy.
- Google wanted to keep it a secret as long as possible.
That combination signals a project that’s well beyond the idea stage. It also suggests that the company may be nearing a public reveal, product announcement, or research debut tied to this technology.
What comes next?
As of now, we don’t know exactly what “AlphaNucleo” will look like—or when it will launch.
But this trademark filing is a major clue.
It shows that Google is investing in a type of artificial intelligence that could decode the most fundamental elements of human biology. It also shows that the company is willing to go to significant lengths to keep the project (and its name) a secret.
Josh Gerben, Esq.
Josh Gerben, Esq. is a nationally recognized trademark attorney and the founder of Gerben IP. Since launching the firm in 2008, he has overseen the registration of over 10,000 trademarks and handled over 1,500 trademark disputes. Josh's practice focuses on building and defending global trademark portfolios for clients. These clients include entrepreneurs, private equity-backed businesses, athletes, celebrities, and public companies. Frequently quoted by major media outlets like CNBC, CNN, The New York Times, and The Wall Street Journal, Josh is widely regarded as a leading authority in trademark law.
Do you need assistance with a trademark matter?
Contact an Attorney Today